-
公开(公告)号:NO20031192A
公开(公告)日:2003-05-13
申请号:NO20031192
申请日:2003-03-14
Applicant: VERTEX PHARMA
Inventor: HALE MICHAEL , JANETKA JAMES , MALTAIS FRANCOIS , CAO JINGRONG , MASHAL ROBERT
IPC: A61K31/42 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K45/00 , A61P1/00 , A61P1/02 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/04 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/20 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/08 , A61P43/00 , C07D413/04 , C07D413/14 , C07D417/14
CPC classification number: C07D413/14 , C07D413/04 , C07D417/14
-
公开(公告)号:HU0202332A2
公开(公告)日:2002-10-28
申请号:HU0202332
申请日:2001-02-05
Applicant: VERTEX PHARMA
Inventor: BAKER CHRISTOPHER , BEMIS GUY , CAO JINGRONG , GREEN JEREMY , HALE MICHAEL , JANETKA JAMES , MALTAIS FRANCOIS , MASHALL ROBERT , MULLICAN MICHAEL , STRAUB JUDITH , TANG QING , XIE XIAOLING
IPC: A61B17/00 , A61F2/02 , A61K31/4155 , A61K31/4178 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/00 , A61L27/00 , A61P1/00 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/00 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P19/00 , A61P21/00 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D231/38 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D403/00
Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R 1-4 , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
-
公开(公告)号:CA2443487A1
公开(公告)日:2002-10-24
申请号:CA2443487
申请日:2002-04-10
Applicant: VERTEX PHARMA
Inventor: CAO JINGRONG , GREEN JEREMY , LEDEBOER MARK , WANG JIAN , HARRINGTON EDMUND , MOON YOUNG-CHOON , GAO HUAI
IPC: C12N15/09 , A61K31/427 , A61K31/506 , A61L33/00 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P3/14 , A61P5/14 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/02 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14 , C12N9/99 , C07D409/02 , C07D409/00
Abstract: The present invention provides compounds of formula (I): or a pharmaceutical ly acceptable derivative thereof, wherein A, B, Ra, R1, R2, R3 and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli; Lck an d Src kinase. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprisi ng the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
-
34.
公开(公告)号:CZ2002534A3
公开(公告)日:2002-07-17
申请号:CZ2002534
申请日:2000-08-11
Applicant: VERTEX PHARMA
Inventor: GREEN JEREMY , BEMIS GUY , GRILLOT ANNE-LAURE , LEDEBOER MARK , SALITURO FRANCIS , HARRINGTON EDMUND , GAO HUAI , BAKER CHRISTOPHER , CAO JINGRONG , HALE MICHAEL
IPC: A61K31/341 , A61K31/4155 , A61K31/4192 , A61K31/42 , A61K31/4439 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/02 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D413/04 , C07D413/14 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/04 , C07D407/14 , C07D417/04 , C07D417/14 , A61K31/4196 , A61K31/4245 , A61P19/00 , A61P7/00
Abstract: The present invention provides compounds of formula I: where R 1 is H, CONH 2 , T( n )-R, or T( n )-Ar 2 , n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
-
公开(公告)号:NO20020713D0
公开(公告)日:2002-02-12
申请号:NO20020713
申请日:2002-02-12
Applicant: VERTEX PHARMA
Inventor: GREEN JEREMY , BEMIS GUY , GRILLOT ANNE-LAURE , LEDERBOER MARK , SALITURO FRANCIS , HARRINGTON EDMUND , GAO HUAI , BAKER CHRISTOPHER , CAO JINGRONG , HALE MICHAEL
IPC: A61K31/341 , A61K31/4155 , A61K31/4192 , A61K31/42 , A61K31/4439 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P7/02 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P11/02 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D413/04 , C07D413/14 , C07D
Abstract: The present invention provides compounds of formula I: where R 1 is H, CONH 2 , T( n )-R, or T( n )-Ar 2 , n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
-
公开(公告)号:BR0104424A
公开(公告)日:2002-01-08
申请号:BR0104424
申请日:2001-02-05
Applicant: VERTEX PHARMA
Inventor: GREEN JEREMY , MULLICAN MICHAEL , BEMIS GUY , XIE XIAOLING , STRAUB JUDITH , TANG QING , MASHALL ROBERT , CAO JINGRONG , HALE MICHAEL , BAKER CHRISTOPHER , MALTAIS FRANCOIS , JANETKA JAMES
IPC: A61B17/00 , A61F2/02 , A61K31/4155 , A61K31/4178 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/00 , A61L27/00 , A61P1/00 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/00 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/06 , A61P19/00 , A61P21/00 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D231/38 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D403/00
Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R 1-4 , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
-
公开(公告)号:AU2023218994A1
公开(公告)日:2024-08-22
申请号:AU2023218994
申请日:2023-02-08
Applicant: VERTEX PHARMA
Inventor: ANGLE SAMANTHA , CAO JINGRONG , COME JON , DAKIN LESLIE A , GALE-DAY ZACHARY , KRUEGER ELAINE B , OLSEN JESSICA H , SENTER TIMOTHY J , SHIMIZU AKIRA J , STONE STEVEN D , WANG TIANSHENG
IPC: C07D495/20 , A61K31/438 , A61K31/444 , A61K31/497 , A61K31/506 , A61P13/12 , A61P35/00 , C07D519/00
Abstract: The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
-
公开(公告)号:JOP20210130A1
公开(公告)日:2023-01-30
申请号:JOP20210130
申请日:2019-12-17
Applicant: VERTEX PHARMA
Inventor: SHI YI , MEDEK ALES , BRODNEY MICHAEL , DAKIN LESLIE A , DORSCH WARREN A , DENIS FRANCOIS , ROSE PETER , SENTER TIMOTHY J , SHRESTHA MUNA , SAYEGH CAMIL , GAGNON KEVIN , FORTIER ANNE , CAO JINGRONG , KRUEGER ELAINE B , COME JON H , LEDFORD BRIAN , NANTHAKUMAR SUGANTHINI S , NICOLAS OLIVIER , HAMEL MARTINE , HU KAN-NIAN , WANG TIANSHENG , WITKOS FAITH
Abstract: غيرمتوفر
-
公开(公告)号:CR20210383A
公开(公告)日:2021-09-22
申请号:CR20210383
申请日:2019-12-17
Applicant: VERTEX PHARMA
Inventor: NANTHAKUMAR SUGANTHINI S , GAGNON KEVIN , DAKIN LESLIE A , HU KAN-NIAN , MEDEK ALES , SHI YI , SHRESTHA MUNA , DENIS FRANCOIS , KRUEGER ELAINE B , WITKOS FAITH , CAO JINGRONG , HAMEL MARTINE , LEDFORD BRIAN , NICOLAS OLIVIER , COME JON H , DORSCH WARREN A , FORTIER ANNE , ROSE PETER , SAYEGH CAMIL , WANG TIANSHENG , BRODNEY MICHAEL , SENTER TIMOTHY J
IPC: A61K31/4025 , A61P13/12 , C07D403/12
Abstract: La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula ( I ), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
-
公开(公告)号:ES2655391T3
公开(公告)日:2018-02-19
申请号:ES10805555
申请日:2010-12-21
Applicant: VERTEX PHARMA
Inventor: ARONOV ALEX , COME JON , DAVIES ROBERT , PIERCE ALBERT , WANG JIAN , NANTHAKUMAR SUGANTHINI , CAO JINGRONG , BANDARAGE UPUL , KRUEGER ELAINE , TIRAN AMAUD , LIAO YUSHENG , MESSERSMITH DAVID , COLLIER PHILIP , GREY RONALD , ODOWD HARDWIN , HENDERSON JAMES , GRILLOT ANNE LAURE
IPC: C07D401/04 , A61K31/352 , A61K31/424 , A61K31/429 , A61P9/00 , A61P29/00 , A61P37/00 , C07D401/14 , C07D405/14 , C07D417/14 , C07D471/04 , C07D471/20 , C07D491/20
Abstract: Compuesto que presenta la fórmula: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, en la que: X1 es N, X2 es N, CH o C-CH3, R1 es un pirazol-4-ilo sustituido opcionalmente con 1 o 2 apariciones de R1a, R1a es cloro, flúor, alifático C1-8, -(CH2)0-2cicloalifático C3-6, -(CH2)0-2-heterocíclico de 5 a 6 elementos que presenta hasta dos heteroátomos seleccionados de entre nitrógeno, oxígeno o azufre, -CN, -C(O)-alifático C1-4, -C(O)NH(alifático C1-4), -C(O)N(alifático C1-4)2, -C(O)O-alifático C1-4, -S(O)2NH(alifático C1-4), - S(O)2N(alifático C1-4)2 o -S(O)2-alifático C 1-4, en los que hasta 3 átomos de carbono no contiguos de dicho alifático o cicloalifático de R1a pueden sustituirse por -O-, -S- o -N(R1b)- y en los que cada uno de dicho alifático, cicloalifático o heterocíclico de R1a se sustituye opcional e independientemente con hasta 4 apariciones de JR, cada JR es independientemente flúor, oxo, -(CH2)0-2CN, -(CH2)0-2CF3 -C(O)R1b, -C(O)N(R1b)2, -C(O)O(R1b), -N(R1b)2, -N(R1b)C(O)R1b, -(CH2)0-2OR1b, fenilo o un heteroarilo de 5 a 6 elementos, heterociclo de 4 a 6 elementos o heteroarilo o heterociclilo bicíclico fusionado de 9 a 11 elementos, presentando cada uno de dichos anillos heteroarilo o heterociclilo que presentan hasta 3 átomos seleccionados de entre nitrógeno, oxígeno o azufre, en el que cada uno de dichos grupos cicloalifático, fenilo, heteroarilo o heterociclilo se sustituyen opcionalmente con hasta 2 R1c, cada R1b se selecciona, independientemente de entre hidrógeno, alifático C1-8, -(CH2)0-1cicloalifático C3-6, -(CH2)0-1heterocíclico C4-6 que presenta hasta dos heteroátomos seleccionados de entre N o O, o dos R1b junto con el átomo al que se encuentran unidos forman un anillo heterocíclico de 5 a 6 elementos, en el que cada grupo alifático, cicloalifático o heterocíclico se sustituye opcionalmente con hasta tres átomos de F o hasta dos grupos -OH, -alquilo C1-2 o -O-alquilo C1-2, cada R1c es, independientemente, flúor, cloro, alifático C1-4, -(CH2)0-2OH, -CN, -C(O)-alifático C1-4 o -C(O)O-alifático C1-4, R2 es hidrógeno, F, Cl, CF3, alifático C1-2, cicloalifático C3-4, -N(CH3)2, -N(CH2)3,-OCF3, -OCHF2 o -O-alifático C1-2, R3 es hidrógeno, alifático C1-6, cicloalifático C3-6, heterocíclico C4-7 que presenta 1 o 2 átomos seleccionados de entre N o O, -(CH2)0-1CF3, -OH, -O-alifático C1-6, -O-cicloalifático C3-6, -O-heterociclilo C3-6 que presenta un átomo de oxígeno, -O(CH2)2O-alifático C1-2 o -O-alquilo C1-2-C(O)O-alifático C1-3 o bencilo, y R4 es hidrógeno o alquilo C1-6, en el que por lo menos uno de entre R3 y R4 no es hidrógeno, o R3 y R4 junto con el carbono al que se encuentran unidos forman un anillo cicloalifático de 3 a 6 elementos, un anillo heterocíclico de 3 a 6 elementos que presenta hasta dos átomos seleccionados de entre N o O, o un alquenilo C2, en el que cada uno de entre dichos grupos alifático, cicloalifático o heterociclilo de R3, R4 o R3 y R4 juntos se sustituyen opcionalmente con hasta tres átomos de F, o hasta dos grupos alquilos C1-2,-C(O)-alquilo C1-4, -C(O)O-alquilo C1-4, -OH o -O-alquilo C1-2, A es N o CRA, B es N o CRB, o A>=B es un átomo de azufre, C es N o CRC, D es N o CRD, E es N o CRE, en el que no más de dos de entre A, B, C, D o E son N, ...
-
-
-
-
-
-
-
-
-